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Hypertrlglyceridemia and lowered apolipoprotein C-H/C-LI! ratio in
uremia: Effect of a fibric acid, clinofibrate. We examined the effects of a
fibric acid, clinofibrate, on lipoprotein metabolism in 12 hyperlipidemic
patients with uremia treated on continuous ambulatory peritoneal
dialysis during a 24 week treatment. Daily dose of clinofibrate was 200
mg for the initial four weeks, 400 mg for the second four weeks, and 600
mg for the subsequent 16 weeks. Serum and very-low density lipopro-
tein (VLDL) triglyceride were decreased by 36% and 48%, respec-
tively. Neither total cholesterol nor apolipoprotein B changed signifi-
cantly, whereas cholesterol was decreased in VLDL and increased in
low (LDL) and high density lipoprotein (HDL) fractions. Post-heparin
plasma lipoprotein lipase (LPL) before treatment was not lower than
the normal value, and we found no change in LPL activity following
clinofibrate. Hepatic triglyceride lipase also did not change. Apoli-
poprotein (apo) C-Il/C-Ill ratio was low as compared to the normal
value before treatment, and the ratio was increased by 38% after the
treatment. Decrease in VLDL triglyceride was associated with increase
in apo C-Il/C-Ill ratio in all the cases. Abnormal enrichment with
triglyceride of LDL and HDL fractions was improved by clinofibrate.
Although one patient had a transient and asymptomatic elevation of
serum creatine phosphokinase, no patient had muscle pain. There was
no accumulation of the drug in the 24 week trial. These results suggest
that clinofibrate is an effective and safe approach to the management of
dyslipidemia in CAPD patients.
Hypertriglyceridemia is one of major lipid abnormalities in
uremic patients [1] and it is often associated with decreased
high density lipoprotein (HDL) cholesterol [2]. Serum total and
low density lipoprotein (LDL) cholesterol are usually within
normal range in uremic patients either treated conservatively or
with hemodialysis (HD) [3]. Although atherogenicity of triglyc-
eride-rich lipoproteins is still controversial, several studies have
shown that hypertriglyceridemia may be an important risk
factor of coronary heart disease. In the Paris Prospective Study
[41, multivariate analysis has shown that hypertriglycendemia
itself is an independent risk factor for coronary heart disease in
patients with impaired glucose tolerance, which is common also
in uremic patients [5]. Low HDL cholesterol is an established
independent risk factor for ischemic heart disease 6, 71, and
this often follows hypertriglyceridemia [8]. The Helsinki Heart
Study indicates that lowering LDL cholesterol and serum
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triglycerides using gemfibrozil with concomitant increase in
HDL cholesterol diminishes the coronary risk in non-uremic
population [9]. There is no available epidemiological study in
uremic patients, and it remains to be determined whether it is
beneficial or not to control lipids and other abnormalities
associated with uremic dyslipidemia.
While elevated production of very-low density lipoprotein
(VLDL) contributes to hyperlipoproteinemia in continuous
ambulatory peritoneal dialysis (CAPD) [10—12], impaired deg-
radation of VLDL is a common cause for hypertriglyceridemia
in HD and CAPD [11, 13]. VLDL is a triglyceride-rich lipopro-
tein which is secreted by the liver. VLDL undergoes hydrolysis
of its triglycerides by the action of LPL, and is converted to
intermediate density lipoprotein (IDL). IDL further loses its
triglycerides and phospholipids by hepatic triglyceride lipase
(HTGL) action, and is converted to low density lipoprotein
(LDL). Unlike HTGL which is hardly affected by apolipopro-
teins, LPL-mediated lipolysis is stimulated by apolipoprotein
(apo) C-Il and inhibited by apo C-Ill. In uremic patients,
post-heparin plasma LPL activity is normal [12, 14, 15] or
reduced [16] and the apo C-II/apo C-Ill ratio is decreased [17,
18].
Several pharmaceutical trials have been made for the treat-
ment of uremic dyslipidemia [19—23]. Fibric acids are one of
theoretically suitable choices for uremic hypertriglyceridemia,
because drugs in this class enhance the degradation of VLDL
[23]. In fact, effective reduction in triglyceride has been re-
ported by several investigators using clofibrate [24—27] and
gemfibrozil [28, 29] in uremia. Unfortunately, their clinical
benefit is limited in patients with renal failure, because these
fibrates are excreted from the kidney; those studies reported
occurrence of adverse effects including rhabdomyolysis and
elevated serum creatine phosphokinase (CPK) due to accumu-
lation of the drugs [26, 27, 29]. Clinofibrate, 2,2'-(4,4'-cyclohex-
ylidene diphenoxy)-2,2'-dimethyldibutilic acid, is a fibric acid
derivative, and 600 mg of it is comparable in hypolipidemic
action to 1500 mg of clofibrate in hyperlipidemic patients
without renal failure [30]. This compound is excreted mostly by
the liver and less than 1% of the administered dose is excreted
into urine in human [31]. Survey study of 11,390 Japanese
showed that side effects of clinofibrate were observed in 2.75%
of the subjects. The primary symptom, found in 1.98% of all
patients surveyed, was gastroenterologic in nature, such as
nausea, vomiting, diarrhea, and abdominal pain. Itchy skin
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and/or skin rash were recorded in 0.74%, and 0.36% of the total
subjects had increases in liver function tests including GOT,
GPT, ALP and y-GTP. Elevation of CPK was noted in 0.11%
(data are from the Phase IV Survey, Sumitomo Pharmaceutical
Co. Ltd.). Therefore, we expected safe use of this drug even in
uremic patients. The aim of this study was to evaluate the
efficacy and safety of clinofibrate for the management of hyper-
lipidemia in CAPD patients.
Methods
Pharmacokinetics in animals
Excretion of clinofibrate into urine and feces was studied in
experimental animals. Clinofibrate and its [4C]-labeled deriva-
tive, in which the second carbon of cyclohexylidene ring was
labeled, were synthesized at Sumitomo Bioscience Institute
(Osaka, Japan). Purity of the ['4C]-derivative was 99% by
radio-thin layer chromatography, and its specific radioactivity
was 6.25 mCi/g. Seven-week-old Sprague-Dawley rats (SLC),
six-week-old ICR-SLC mice and a one-year-old beagle dog
were used in the experiment. They were fed ad libitum on
standard chow diets (CE-2 for rats and mice and CD-5 for the
dog; Clea Japan Inc., Tokyo, Japan). Clinofibrate was admin-
istered orally or intravenously at a dose of 30 mg/kg body
weight. Animals were kept in the metabolic cages to collect
urine and feces separately. Aliquots of urine and feces speci-
mens were measured for radioactivity after appropriate treat-
ments.
Patients
Twelve uremic patients treated with CAPD, 10 men and 2
women, were entered the study with informed consent. All
were Japanese. They had hypertriglyceridemia of serum triglyc-
eride >150 mg/dl, and three of them also showed hypercholes-
terolemia of total cholesterol >220 mg/dl. Mean (range) age was
54 (40 to 73) years and mean dialysis period was 62 (8 to 167)
months. Body mass index was 23.0 (18.7 to 26.2) kg/rn2.
Underlying renal diseases included chronic glomerulonephritis
(N = 9), hypertensive nephrosclerosis (N = 1), polycystic
kidney (N = 1), and renal tuberculosis (N = 1). Patients with
diabetic nephropathy were excluded. No one required insulin
for glycemic control, and their fasting plasma glucose was 97
(81 to 115) mg/dl even taking glucose-containing peritoneal
dialysate. Serum creatinine and blood urea nitrogen were 13.1
(9.2 to 17.6) mg/dl and 58.5 (34.5 to 79.1) mg/dl, respectively.
They did not take other drugs which affect serum lipids at least
six months before and during the study. These patients used
three or two bags of 1 to 1.5 liter intraperitoneal dialysate
containing 1.5% glucose and one or two bags of I to 1.5 liter
2.5% glucose dialysate (Dianeal 1.5 and 2.5, Baxter Healthcare
Corp., Round Lake, Illinois, USA) every day. Dialysis sub-
scription was not changed during the study. The patients had
dietary education, in which the recommended daily intake was
30 to 35 kcal/kg ideal body weight minus 400 kcal, considering
peritoneal glucose absorption. Actual intake was almost 1,300
to 1,500 kcallday included 50 to 60% of total energy for
carbohydrate, 60 to 70 g of protein and 35 to 45 g of fat. They
were told not to change their eating habits during the study.
Study protocol
The patients took clinofibrate (Lipoclin®, Sumitomo Pharma-
ceuticals Co. Ltd., Osaka, Japan) orally with daily dose of 200
mg for four weeks, and the dose was increased to 200 mg twice
daily for the following four weeks. Finally, 200 mg clinofibrate
thrice daily, which is the recommended daily dosage for non-
uremic hyperlipidemics, was given for 16 weeks. The total
period was 24 weeks. Blood was sampled four weeks before
(week —4) and at the start (week 0) of clinofibrate treatment
(control period) and 4, 8, 12 and 24 weeks after the initiation of
the administration (treatment period) for the measurements of
serum total cholesterol, triglyceride, total protein, albumin,
GOT, GPT, CPK, glucose and hemoglobin Aic. Serum lipopro-
tein fractions were analyzed at weeks 0, 4, 8, 12 and 24.
Apolipoproteins, post-heparin LPL and hepatic triglyceride
lipase (HTGL) were measured at weeks 0 and 24. Post-heparin
plasma for LPL and HTGL activities was obtained 10 minutes
after intravenous injection of a Novo sodium heparin (30 lU/kg
body wt). All blood samplings were made in the morning after
at least a 12 hour fast.
Analytical procedures
Serum lipoproteins were analyzed by one-step preparative
ultracentrifugation originally described by Bronzert and Brewer
[32] with a modification [33]. Cholesterol and triglyceride con-
centrations were measured using enzymatical kits [12] in whole
serum and lipoprotein fractions (d = density) (VLDL, d < 1.006
g/ml; IDL, d 1.006 to 1.019 g/ml; LDL, d = 1.019 to 1.063
g/ml; HDL2, d = 1.063 to 1.125 g/ml; HDL3, d> 1.125 g/ml).
Apolipoproteins (apo) A-I, A-lI, B, C-LI, C-Ill and E were
measured by immunoturbidimetry (ApoAuto, Daiichi, Tokyo).
LPL and HTGL activities in post-heparin plasma were mea-
sured by the method described elsewhere [12]. Briefly, in LPL
activity assay, [3H]-trioleinlgum arabic emulsion was preincu-
bated with activator serum to optimize the enzyme reaction. A
small amount of post-heparin plasma (5 sl/assay), pretreated
with sodium dodecyl sulfate (SDS) to inhibit HTGL, was used
to minimize the confounding effects of C-apolipoproteins in-
cluded in the sample. LPL activity measured by this method is
proportional to LPL protein concentration in the post-heparin
plasma as demonstrated for both uremic and non-uremic sub-
jects [33]. HTGL activity assay mixture contains no activator
serum, no SDS, but high NaC1 (1 M) to inhibit LPL. HTGL
activity measured by this method is also proportional to HTGL
protein mass in the post-heparin plasma [33]. Clinofibrate
concentration was measured in plasma and peritoneal effluent
by GC-MS (Sumitomo Chemical).
Statistics
Data were expressed as mean s, unless otherwise men-
tioned. Difference among means of repeated measurements was
evaluated by two-way analysis of variance (ANOVA) with
Scheffe-type multiple comparison. Significance level was set at
P < 0.05.
Results
Pharmacokinetics of clinofibrate
It was evidenced by TLC and GC-MS that most of adminis-
tered radiolabeled clinofibrate was present in the unmetabolized
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Urine Feces
Oral administration
Rat (N = 4) 0.15 0.03 85.36 2.48
Mouse (N = 3) 1.25 0.49 73.20 8.52
Dog(N= 1) 1,8 60.9
Intravenous injection
Rat (N = 3) 0.09 0.01 75.56 2.49
Dog (N = 1) 8.03 58.74
form in serum, urine and feces with a bit of its monoester form.
As shown in Table 1, radioactivity of ['4C1-clinofibrate was
much greater in feces than in urine after oral administration.
This was also the case with the results after intravenous
injection among the three animal species studied. In rats, more
than 95% of the administered clinofibrate was excreted into
feces within 48 hours following either oral or intravenous
administration. These results indicate that the main route of
clinofibrate excretion was hepatic rather than renal.
Changes in serum cholesterol and triglyceride
Figure 1 gives the changes in serum triglyceride and choles-
terol concentrations before and during clinofibrate treatment.
Before the administration (control period), there was a slight
increase in triglyceride level, but it was not significant (242 21
mg/dl, mean SE, at week —4 and 271 34 mg/dl at week 0).
Clinofibrate reduced serum triglyceride, and the values were
203 20, 202 17, and 181 23 mgldl at weeks 4, 8 and 12,
respectively. Prolonged administration maintained the lowered
triglyceride level. The final concentration was 174 22 mg/dl at
week 24 and a maximum reduction in serum triglycerides of
36% was observed by week 24. Serum cholesterol level, how-
ever, did not show significant change during the study.
Changes in triglyceride and cholesterol distribution among
VLDL, JDL and LDL fractions
Results of lipoprotein analysis in VLDL, IDL and LDL were
presented in Figures 2 and 3. Baseline VLDL, IDL and LDL
triglycerides were 189.8 34.0, 18.4 2.6, and 43.7 4.1
mg/dl, respectively (Fig. 2). Clinofibrate resulted in a marked
reduction in VLDL triglyceride, and the values were 122.7
18.8, 122.2 15.9, 107.7 22.5, and 97.8 20.1 mg/dl at weeks
4, 8, 12 and 24, respectively. The reduction rate in VLDL
triglyceride was 48% at week 24. The decrease in VLDL
triglyceride accounted for the most part of serum triglyceride
reduction. There was no significant change in either IDL or
LDL triglyceride.
Baseline VLDL, IDL, and LDL cholesterols were 70.7 6.7,
21.1 2.7, and 81.4 8.8 mgldl, respectively (Fig. 3). Clinofi-
brate reduced the VLDL cholesterol level, and the values were
56.1 4.7, 52.9 3.6, 50.6 5.7,and 53.3 7.6 mgldl at weeks
4, 8, 12 and 24, respectively. The change was significant at
weeks 8 and 12. IDL cholesterol did not change significantly.
LDL cholesterol levels showed a significant increase following
Time, weeks
Fig. 1. Changes in serum cholesterol (0) and triglyceride (S)fo!lowing
clinofibrate. Daily dose of clinofibrate was increased from 200 to 400
and finally 600 mg/day. Data are mean SE. *P < 0.05 vs. baseline
value at 0 week by Scheffe-type multiple comparison.
clinofibrate, and the values were 112.5 9.1, 115.6 10.7,
105.4 7.3, and 105.8 7.3 mg/dl at weeks 4, 8, 12 and 24,
respectively.
Changes in post-heparin plasma LPL and HTGL activities
Activity assays for LPL and HTGL in post-heparin plasma
were performed before and after 24-week clinofibrate treatment
(Fig. 4). Post-heparin plasma LPL activity in the baseline
period was 1.85 0.20 mol/hr/m1, which was not different
significantly from the normal value. The post-heparin plasma
HTGL level for 10 men was 11.57 1.71 smoUhr/m1 before
treatment, which was low compared with the control values.
The pretreatment levels of post-heparin plasma HTGL activity
for the two women were 4.44 and 7.71 mol/hr/ml, respectively,
and both values were lower than the normal mean (7.96
jmolIhr/ml). Clinofibrate treatment did not change the mean
LPL or mean HTGL activity in post-heparin plasma.
Changes in apolipoproteins
Table 2 gives changes in apolipoprotein (apo) concentrations.
There was no statistically significant change in apo A-I, A-H or
B. Apo C-Ill and apo E reduced after clinofibrate treatment.
Apo C-I!, however, did not change during the study. Therefore,
Table 1. Excretion of ['4C]-clinofibrate into urine and feces during
24 hours
Animals were administered 30 mg/kg body weight of ['4C] labeled
clinofibrate orally or intravenously. Urine and feces were collected
separately during 24 hours for the measurement of radioactivity.
Results were expressed as % excreted of the total dose. Data are mean
SE.
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Time, weeks
Fig. 2. Change in trig!yceride distribution among VLDL (0), JDL (U),
LDL (Li) fractions and whole serum (I). Data are mean SE. * D <
0.05 vs. baseline value by Scheffe-type multiple comparison. Normal
values (mean SD ranges) adopted from our previous work [33]: VLDL
triglycerides, 30.2 22.0 mg/mI; IDL triglycerides, 5.7 3.9 mg/dl;
LDL triglycerides, 19.6 13.7 mg/dl.
apo C-Il/C-Ill ratio, which was low before treatment as com-
pared to the reference value, elevated significantly by 38%
following clinofibrate.
Relationship between the apo C-Il/C-Ill ratio and VLDL
triglyceride
We examined a possible relationship between the change in
apo C-Il/C-Ill ratio and the change in VLDL triglyceride level
in individual subjects (Fig. 5). The decrease in VLDL triglyc-
eride was associated with the increase in apo C-Il/C-Ill ratio in
all the subjects.
Changes in HDL lipids and HDL composition
Lipid levels and composition of HDL fraction were compared
before and after the 24-week clinofibrate treatment (Table 3).
HDL cholesterol significantly increased by 15%. HDL triglyc-
eride decreased by 20% with a borderline significance. The
triglyceride to cholesterol ratio in HDL fraction was signifi-
cantly reduced by 34%, indicating that clinofibrate resulted in
triglyceride depletion and cholesterol enrichment of the HDL
fraction. The increase in the molar ratio of HDL cholesterol to
apo A-I plus A-Il was significant. The molar ratio of HDL
triglyceride to apo A-I plus A-I! was decreased by 12%, but the
change was not statistically significant.
0 4 8 12 24
Time, weeks
Fig. 3. Change in cholesterol distribution among VLDL (0), IDL (U),
LDL (D) fractions and whole serum (•). Data are mean SE. * D
0.05 vs. baseline value by Scheffe-type multiple comparison. Normal
values (mean SD range) adopted from our previous work [33]: VLDL
cholesterol, 23.0 7.3 mg/mI; IDL cholesterol, 5.3 5.4 mg/dl; LDL
cholesterol, 103.6 33.8 mg/dl.
Change in LDL composition
There was an increase in cholesterol in LDL fraction,
whereas the triglyceride in LDL did not change as indicated
above. Therefore, the triglyceride to cholesterol ratio in LDL
fraction decreased by 25% (0.586 0.069 vs. 0.439 0.038
mg/mg, baseline vs. week 24, P 0.01 12).
Adverse effect and changes in routine biochemical tests
following clinofibrate
No patient complained muscular pain during the 24 week
study. Table 4 gives the routine biochemical tests including
serum total protein, albumin, GOT, GPT, CPK, plasma glucose
and hemoglobin A lc, showing no apparent abnormality induced
by clinofibrate. Asymptomatic minor elevation of CPK (337
U/liter) was recorded at week 24 in one female patient. After
that, her CPK fell to the normal range without discontinuation
of the drug.
Clinofibrate concentration in plasma and peritoneal effluent
at week 24
To examine a possible accumulation of clinofibrate in plasma
of the patients, we measured the concentration of the com-
pound in fasting plasma at week 24. Plasma clinofibrate con-
centration was 7.08 1.30 (range 0.02 to 13.93) g/ml. These
values were rather low when compared to the value in non-
uremic subjects; plasma clinofibrate concentration reached
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0
A LPL
U I
B HTGL
Week 0 Week 24
Fig. 4. Post-heparin plasma LPL (A) and HTGL (B) activities before
and after clinofibrate treatment. Closed and open circles indicate men
and women, respectively. Normal values (mean SD ranges): LPL,
2.09 0.54 tmol/hr/ml; HTGL, 14.33 6.00 prnol/hr/ml for men and
7.96 4.32 smol/hr/ml for women.
Week 0 Week 24 P value
Apo A-I, mg/dl 106 4 99 7 NS
Apo A-I!, mg/dl 23.3 1.4 20.8 1.3 0.0518
Apo B, mg/dl 119.7 5.0 120.9 4.8 NS
Apo C-Il, mg/dl 4.6 0.5 4.5 0.8 NS
Apo C-HI, mg/dl 21.9 2.3 15.6 2.2 0.0161
Apo E, mg/dl 7.2 0.6 5.6 0.5 0.0025
Apo B/A-I ratio, mg/mg 1.14 0.05 1.27 0.08 0.0462
Apo C-Il/C-Ill ratio, mg/mg 0.21 0.01 0.29 0.02 0.0002
Apo E/C-IH ratio, mg/mg 0.38 0.06 0.46 0.09 NS
Difference between means was evaluated by two-way ANOVA.
Abbreviation apo is apolipoprotein.
Data are mean SE. Reference values (mean SD) of healthy
subjects in our laboratory [12] are: apo A-I, 119 22 mg/dl; apo A-Il,
28.2 5.6 mg/dl; apo B, 86 18 mg/dl; apo C-lI, 2.9 1.2 mg/dl; apo
C-Ill, 7.8 3.0 mg/dl; apo E, 4.6 1.4 mg/dl; apo B/A ratio, 0.75
0.18 mg/mg; apo C-Il/C-Ill ratio, 0.38 0.09 mg/mg; apo E/C-lII ratio,
0.62 0.22 mg/mg.
plateau in five days with a mean of 20 jg/ml after repeated
administration of 600 mg/day of the drug in healthy adults [31].
Clinofibrate in peritoneal effluent was detectable in 11 out of the
12 patients, and the mean daily amount was 191 mg/day (range
0 to 460 mg/day).
Discussion
Our data demonstrated that clinofibrate, one of the fibric acid
derivatives, was effective and safe for the reduction of VLDL in
Apo C-Il / C-Ill ratio, mg/mg
Fig. 5. Relationship between changes in apo C-fl/C-Ill ratio and
VLDL triglyceride. Each plots indicate individual cases. Closed circle
and arrowhead indicate the values at weeks 0 and 24, respectively.
Table 3. Changes in HDL lipids and HDL composition following
clinofibrate treatment
Week 0 Week 24 P value
HDL-C, mg/dl 31.9 2.8 36.7 2.5 0.0310
HDL-TG, mg/dl 19.3 1.4 15.5 0.8 0.0568
HDL-TG/HDL-C, 0.661 0.073 0.438 0.032 0.0055
mg/mg
HDL-C/(A-I + A-Il), 12.6 0.9 16.2 0.8 0.0011
mol/mol
HDL-TG/(A-I ÷ A-Il), 3.44 0.29 3.06 0.17 NS
mol/mol
Difference of means was evaluated by two-way ANOVA.
Abbreviations are: HDL-C, HDL cholesterol; HDL-TG, HDL trig-
lyceride; A-I + A-Il, apolipoproteins A-I + A-Il. Data are mean SE.
Reference values (mean SD) of healthy subjects in our laboratory [33]
are: HDL-C, 55.6 13.0 mg/dl; HDL-TG, 12.7 4.5 mg/dl; HDL-TG/
HDL-C, 0.237 0.100 mg/mg; HDL-C/(A-I + A-lI), 23.0 6.0
mol/mol; HDL-TG/(A-I + A-Il), 2.38 1.05 mol/mol.
CAPD patients. Its usual daily dose of 600 mg resulted in a 36%
decrease in serum triglyceride and 48% decrease in VLDL
triglyceride. Also, clinofibrate improved compositional abnor-
mality in LDL and HDL fractions, and increased HDL choles-
terol significantly. Although one patient had a transient and
asymptomatic increase in CPK, no one had muscle pain in the
24 week trial. And we found no accumulation of this compound
in the CAPD patients.
Hypertriglyceridemia in CAPD is caused by elevated produc-
tion and impaired lipolysis of VLDL [10—121. Peritoneal glucose
load and nephrosis-like effect by protein loss through peritoneal
route may account for the increased production. Impaired
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Table 2. Changes in apolipoproteins following clinofibrate
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Table 4. Routine laboratory data during clinofibrate treatment
Week 0 Week 4 Week 8 Week 12 Week 24
Total protein, 7.1 0.5 7.0 0.4 7.2 0.6 7.0 0.6 6.8 0.6
gld!
Albumin, g/d! 3.7 0.2 3.6 0.2 3.6 0.2 3.6 0.2 3.6 0.2
GOT,IU/liter II 5 11 5 17 9 13 6 12 7
GPT,IU/liter 10±6 10±5 15±9k 11±7 11±7
CPK,IU/!iter 103±57 117±65 116±63 116±45 140±78
Glucose, 95 13 100 19 96 11 91 16 97 11
mg/dl
HbAlc, % 6.4 0.5 6.3 0.7 6.5 0.6 6.4 0.5 6.3 0.5
Abbreviations are: GOT, glutamic-oxalacetic transaminase; GPT,
glutamic-pyruvic transaminase; CPK, creatine phosphokinase. Data are
mean SD. Normal ranges of the parameters are: total protein, 6.7 to
8.3 g/dl; albumin, 4.0 to 5.0 g/dl; GOT, 10 to 40 lU/liter; GPT, 4 to 50
lU/liter; CPK 24 to 195 U/liter; glucose 70 to 100 mg/dl; HbAlc, 4.8 to
5.8%.
aP < 0.05 vs. 0 week by Scheffe-type multiple comparison
lipolysis is a common feature in uremic patients regardless of
the modes of dialysis therapy [11, 13], and it is attributable to
lowered LPL function in vivo. However, reduction of LPL
activity in post-heparin plasma is not a universal finding in
uremic patients; some demonstrated lowered post-heparin
plasma LPL activity [16], while others failed to detect it [12, 14,
15]. This apparent discrepancy could be due to an impaired
LPL-cofactor function in uremia. Patients with apo C-Il defi-
ciency, for example, have a critically impaired LPL-mediated
lipolysis, although their post-heparin plasma LPL activity is
normal when measured in the presence of exogenous activators
[34]. VLDL is degraded by LPL into VLDL-remnant (IDL) [35]
and finally converted to LDL by the action of HTGL [36]. Apo
C-Il is required as an essential cofactor of LPL [37] while apo
C-Ill inhibits LPL action [38]. Apo C-Il/C-Ill ratio renders
susceptibility of the substrate lipoprotein to LPL action. Previ-
ous studies found that uremic patients had decreased apo
C-Il/C-Ill ratio in VLDL [17, 18], HDL [17], and serum [12].
These previous findings suggest that a decreased post-heparin
LPL is crucial in some uremics, and that a low apo C-Il/C-Ill
ratio is also important in other patients as the cause for the
impaired lipolysis. Eisenberg et al showed in their in vitro
lipolysis experiments that a lowered apo C-Il/C-Ill ratio was
not a result of impaired catabolism of VLDL [39]. A recent
transgenic mice experiment has demonstrated the causative
role of relative increase of apo C-Ill for hypertriglyceridemia
[40].
In the current study, clinofibrate did not change total choles-
terol or apo B level, whereas the treatment decreased triglyc-
eride and cholesterol in VLDL fraction and increased LDL
cholesterol. These alterations indicate a triglyceride reduction
with a shift in cholesterol distribution from VLDL to LDL. This
finding is compatible with enhanced delipidation in VLDL-IDL-
LDL cascade following clinofibrate, although we could not rule
out a possible suppression of VLDL production by clinofibrate.
In spite of hypertriglyceridemia, the post-heparin plasma LPL
activity of our CAPD patients was not reduced in the baseline
period and LPL did not change during clinofibrate treatment.
Post-heparin plasma LPL activity in our laboratory is in a direct
relation to LPL enzyme protein level [33]. These findings
suggest that LPL enzyme level itself did not account for either
the elevation of VLDL before treatment or decrease in VLDL
following clinofibrate. On the other hand, basal apo C-Il/C-Ill
ratio was lower than normal and clinofibrate treatment restored
the ratio. Furthermore, the reduction in VLDL triglyceride was
associated with the increase in apo C-Il/C-Ill ratio in all the
cases. These data strongly suggest that clinofibrate enhanced
VLDL degradation by affecting C-apolipoproteins, without
increasing the post-heparin LPL enzyme level.
A previous trial with clofibrate for hypertriglyceridemia in
HD patients showed a marked decrease in serum triglyceride
with a selective increase in LPL but not HTGL activity in
post-heparin plasma [41]. Two recent studies with gemfibrozil
in uremic patients without dialysis [42] and treated with CAPD
[43] demonstrated an effective reduction of VLDL triglyceride
with significant increase in both LPL and HTGL activities. In
those studies, post-heparin plasma LPL activity was lower than
normal before treatment. No data on C-apolipoproteins were
available in the three studies. In contrast, we found that
clinofibrate also effectively promoted VLDL degradation with-
out increasing post-heparin plasma LPL or HTGL activity, but
the drug improved apo C-Il/C-Ill ratio. In non-uremic hyper-
lipidemic patients, post-heparin LPL activity was increased [44,
45], and HTGL was not changed [44] after administration of
clinofibrate. They did not report their normal ranges of the
enzymes or changes in apolipoproteins. These fibrates seem to
have different actions, or the LPL response to drugs may be
variable depending on the pretreatment level of the enzyme or
underlying disease.
HDL fraction was abnormally enriched with triglyceride
before the treatment, but this compositional abnormality was
restored, and HDL cholesterol was increased following clinofi-
brate. We found no increase in HTGL, which hydrolyzes
triglyceride in HDL [46]. Then, these effects of clinofibrate
could be attributable to reduced lipid transfer between lipopro-
teins. Cholesteryl ester transfer protein (CETP) promotes trans-
fer of cholesteryl ester from HDL to VLDL, and transfer of
triglyceride in the opposite direction [47]. Although CETP is the
rate-limiting factor for the lipid transfer in severe hypertriglyc-
eridemia, VLDL triglyceride drives the reaction rate in moder-
ate hypertriglyceridemia [48]. Our recent work has shown that
HDL becomes triglyceride-rich and cholesterol-poor in propor-
tion to elevation in VLDL triglyceride [33]. Therefore, lowered
VLDL triglyceride by clinofibrate accounts for the observed
change of lipid composition in HDL fraction. Because lipid
transfer also takes place between VLDL and LDL [47], reduc-
tion of VLDL triglyceride explains cholesterol enrichment and
triglyceride depletion of LDL after clinofibrate.
Since part of HDL precursor particles is derived from surface
remnant generated during degradation of triglyceride-rich ii-
poproteins [49], increased HDL apolipoproteins as well as HDL
cholesterol were expected during the study. HDL cholesterol
was increased by clinofibrate treatment, whereas apolipopro-
teins A-I and A-Il did not. These findings may indicate that
HDL was enriched with cholesterol but the number of HDL
particles did not increase in plasma. We speculate that part of
newly generated HDL precursors was lost into peritoneal
drainage. Lipoproteins are shown to leak through the peritoneal
barrier into peritoneal dialysate, and smaller particles are more
leaky [50]. Loss of small particles containing A-apolipoproteins
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may explain the significant but modest increase of HDL cho-
lesterol which was observed with marked reduction of VLDL
triglyceride following clinofibrate.
There was no accumulation of clinofibrate in blood and no
related adverse effect in CAPD patients. Plasma clinofibrate
concentration was rather lower than that in healthy adults. Part
of the administered dose was detected in peritoneal dialysate,
indicating the loss of the compound into peritoneal drainage.
We speculate that no accumulation of clinofibrate in CAPD
patients was due mainly to hepatic excretion of the drug, but
not due to the loss through peritoneal route, because its plasma
concentration was not elevated even in a patient without
detectable peritoneal leak of the drug. Safety in hemodialysis
patients, however, remains to be established. In addition, it
should be kept in mind that clinofibrate increased LDL choles-
terol. This suggests an unfavorable lipoprotein change in some
patients. It may be better to limit the use of this drug only for
type IV but not for type lIb hyperlipidemia, or additional
treatment, such as bile acids binding resins and low-dose
HMG-CoA reductase inhibitors, may be needed for increased
LDL cholesterol.
The present study has shown that relative proportion of apo
C-Il and C-Ill can be modulated by a drug like clinofibrate, and
that the modulation results in enhanced degradation of VLDL.
In other words, the results suggest a crucial role of apo C
abnormality in the pathogenesis of uremic hypertriglyceridemia
at least in some patients. For the amelioration of this abnormal-
ity, clinofibrate appears to be an effective and safe choice. The
mechanism for the decreased apo C-Il/C-Ill ratio in uremia is
not proven in this study. The role of the kidney for degradation
of the apolipoproteins is unknown. There may be some rela-
tionship between altered calcium homeostasis and apolipopro-
tein metabolism, and genetic factors may be present because
the reduced apo C-Il/C-Ill ratio also appears in some patients
with primary hypertriglyceridemia [51]. Further studies will be
necessary to evaluate what is responsible for the change in apo
C-Il and C-Ill in uremia, and whether pharmaceutical treatment
of dyslipidemia reduces the cardiovascular risk in chronic renal
failure.
Reprint requests to Yoshiki Nishizawa, M.D., Second Department of
InternalMedicine, Osaka City University Medical School, 1-5-7, Asahi-
machi, Abeno-ku, Osaka 545, Japan.
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